COVID-19 and thalassaemia: A position statement of the Thalassaemia International Federation.
Eur J Haematol
; 105(4): 378-386, 2020 Oct.
Article
in English
| MEDLINE | ID: covidwho-612275
ABSTRACT
OBJECTIVES:
Many patients with haemoglobinopathies, including thalassaemia and sickle cell disease, are at increased risk of developing severe complications from the coronavirus disease 2019 (COVID-19). Although epidemiologic evidence concerning the novel coronavirus (SARS-CoV-2) infection in these patients is currently lacking, the COVID-19 pandemic represents a significant challenge for haemoglobinopathy patients, their families and their attending physicians.METHODS:
The present statement summarizes the key challenges concerning the management of haemoglobinopathies, with particular focus on patients with either transfusion-dependent or non-transfusion-dependent thalassaemia, identifies the gaps in knowledge and suggests measures and strategies to deal with the pandemic, based on available evidence and expert opinions. Key areas covered include patients' risk level, adaptation of haemoglobinopathy care, safety of blood transfusions, blood supply challenges, and lifestyle and nutritional considerations.CONCLUSIONS:
The proposed measures and strategies may be useful as a blueprint for other disorders which require regular hospital visits, as well as for the timely adaptation of patient care during similar future pandemics.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Thalassemia
/
COVID-19
Type of study:
Diagnostic study
/
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Eur J Haematol
Journal subject:
Hematology
Year:
2020
Document Type:
Article
Affiliation country:
Ejh.13476
Similar
MEDLINE
...
LILACS
LIS